Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Synthorx
La Jolla, California, United Statessynthorx.com ↗
- Ownership
- Private
- Employees
- ~11
- Development stage
- Other
01
Overview
Synthorx developed a proprietary Expanded Genetic Alphabet platform that enabled the creation of optimized protein therapeutics ("Synthorins") with improved pharmacological properties. Its lead candidate, THOR‑707, an engineered IL‑2 variant for cancer immunotherapy, advanced into clinical trials. The company was acquired by Sanofi in January 2020 before any product reached commercialization
- Therapeutic areas
- ImmunologyOncology
- Modalities
- Protein therapeutics (engineered proteins called "Synthorins")Cytokines (notably interleukins such as IL-2 and IL-15 variants)
- Industry
- Biotech
Beyond the preview
Go deeper on Synthorx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Synthorx.